Market Research Logo

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2018

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2018

Summary

Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens throug


Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 8 (CD288 or TLR8) - Overview
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development
BioNTech AG
Celgene Corp
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
Janus Biotherapeutics Inc
MedImmune LLC
Nektar Therapeutics
Pfizer Inc
Vivelix Pharmaceuticals Ltd
Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles
854-A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUCPT-8m - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-1508052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab + MEDI-9197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DV-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-6742 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-9688 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMO-9200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INGMM-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JB-6121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-9197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
motolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NKTR-262 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resiquimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resiquimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSLV-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTX-1463 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products
Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products
Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones
Featured News & Press Releases
Oct 11, 2018: Gilead to present data on Hepatitis B drug candidate GS-9688 at The Liver Meeting 2018
Jul 03, 2018: Recent Studies Unveil Clues to Using Immunotherapy as Cancer Treatment
Apr 15, 2018: Nektar Therapeutics Presents New Preclinical Data on NKTR-262 at the American Association for Cancer Research (AACR) Annual Meeting 2018
Apr 11, 2018: Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors
Nov 07, 2017: Nektar to Present New On Drug Candidate NKTR-262 At 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting
Aug 22, 2016: Resolve Therapeutics Announces Publication Of Clinical Data Demonstrating The Role Of Circulating RNA In Systemic Lupus Erythematosus
Jul 12, 2016: Mayo Clinic researchers identify potential immunotherapy drug combination
May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference
Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study
May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors
Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer
Oct 14, 2014: Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200
Sep 03, 2014: Ludwig Cancer Research And Cancer Research Institute Collaborate On Evaluation Of Ventirx's Investigational Immunotherapy
Sep 02, 2014: VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer
Jul 16, 2014: Resolve Initiates Phase 2 Clinical Study in SLE
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by BioNTech AG, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by Dynavax Technologies Corp, H2 2018
Pipeline by Eisai Co Ltd, H2 2018
Pipeline by Galderma SA, H2 2018
Pipeline by Gilead Sciences Inc, H2 2018
Pipeline by Janus Biotherapeutics Inc, H2 2018
Pipeline by MedImmune LLC, H2 2018
Pipeline by Nektar Therapeutics, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Vivelix Pharmaceuticals Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report